Validating the OCS-Plus against a clinical standard: A brief report

Rebecca Roberts; Reena Vohora; Sam S Webb; Nele Demeyere

doi:10.1111/jnp.12369

Validating the OCS-Plus against a clinical standard: A brief report

J Neuropsychol. 2024 Apr 23. doi: 10.1111/jnp.12369. Online ahead of print.

Authors

Rebecca Roberts^{1

2}, Reena Vohora^{2

3}, Sam S Webb³, Nele Demeyere⁴

Affiliations

¹ Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
² Oxford Institute of Clinical Psychology Training and Research, Isis Education Centre, Warneford Hospital, Oxford, UK.
³ Department of Experimental Psychology, Oxford University, Oxford, UK.
⁴ Nuffield Department of Clinical Neurosciences, OUH John Radcliffe Hospital, Oxford, UK.

PMID: 38654444
DOI: 10.1111/jnp.12369

Abstract

This research aimed to determine the sensitivity and clinical validity of the OCS-Plus, a stroke-specific tablet-based cognitive screening tool, in comparison with the MoCA, a routinely used screening tool, after stroke. Eighty-six patients were recruited from Oxfordshire stroke wards over a 22-month period and completed both screens. Overall, we found that the OCS-Plus has good convergent validity and excellent sensitivity when compared with the MoCA. The OCS-Plus is therefore of potential benefit to those seeking a sensitive screening tool.

Keywords: cognitive impairment; cognitive screening; neurorehabilitation; stroke; validation.

Abstract

Grants and funding